Y. Cheng

发表

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study.

Q. Wang, W. Zhong, Q. Zhou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma

Y. Cheng, Wei Ma, Kai Wang, 2012 .

493 Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year

Ching-lung Lai, E. Gane, Y. Cheng, 2006 .

Circulating Tumor Cell Detection In Epithelial Ovarian Cancer Using Dual-Component Antibodies Targeting EpCAM And FRα

Y. Cheng, Yi Yao, Q. Song, 2019, Cancer management and research.

First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre

Y. Cheng, L. Yang, Y. Liu, 2015, International journal of clinical practice. Supplement.

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

S. Gettinger, Han Chang, T. Ciuleanu, 2018, Annals of Oncology.

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

N. Reinmuth, Ying Cheng, A. Mansfield, 2019, Annals of Oncology.

1331PDetection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms

S. Patel, Y. Wu, C. Zhou, 2017 .

In vitro expansion and differentiation of rat pancreatic duct-derived stem cells into insulin secreting cells using a dynamicthree-dimensional cell culture system.

Y. Cheng, L. Yang, Y. Liu, 2016, Genetics and molecular research : GMR.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

T. Mok, Y. Ichinose, M. Maemondo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double‐blind, phase III study

Z. Zhang, B. Han, J. Li, 2017, European journal of cancer care.

Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma

Y. Cheng, J. Xu, L. Liu, 2013, Clinical and Translational Oncology.

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407

A. Tafreshi, L. Paz-Ares, M. Pietanza, 2019, Annals of Oncology.

Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

P-C. Yang, Y. Cheng, H. Murakami, 2016 .

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.

J. Barrett, S. Ramalingam, B. Cho, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Recovery of humic substances from landfill leachate via 2500 Da ultrafiltration membrane

B. Han, Y. Cheng, G. Qi, 2011 .

Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC

L. Paz-Ares, Y. Cheng, Hongjun Gao, 2019, Annals of Oncology.

Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.

S. Gettinger, S. Peters, T. Ciuleanu, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.

Yi-long Wu, W. Feng, W. Zhong, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors

Y. Cheng, Y. Xu, J. Wang, 2021, Annals of Oncology.

2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC

H. Zhang, N. Yang, Yuxiang Chen, 2022, Annals of Oncology.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

T. Mok, Y. Ichinose, M. Maemondo, 2017 .

Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC.

L. Zhang, Se-Hoon Lee, C. Zhou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma

Z. Wainberg, B. Ma, Y. Cheng, 2021, Annals of Oncology.

Prognostic factors for 495 nonoperative esophageal squamous cancer patients receiving IMRT plus chemotherapy: A retrospective analysis.

Y. Cheng, X. Di, X. Ge, 2022, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Consensus for HER2 alterations testing in non-small-cell lung cancer

F. Hirsch, T. Mitsudomi, X. Wang, 2022, ESMO open.

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

Yi-long Wu, Y. Wu, C. Zhou, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

P. Jänne, D. Planchard, M. Aregay, 2022, Annals of Oncology.

Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC).

Se-Hoon Lee, C. Zhou, Y. Cheng, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.

K. Muro, Y. Cheng, S. Qin, 2021, ESMO open.

Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: Analysis of the Chinese subgroup in KEYNOTE-181

L. Shen, Y. Cheng, S. Qin, 2019, Annals of Oncology.

P1.01-61 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer

Y. Wang, J. Yang, Y. Wu, 2019, Journal of Thoracic Oncology.

JCSE01.09 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer

Y. Wang, J. Yang, Y. Wu, 2019, Journal of Thoracic Oncology.

LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

Q. Wang, N. Cui, Y. Wu, 2021, Annals of Oncology.

OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

Y. Wu, Y. Cheng, M. Chen, 2022, Journal of Thoracic Oncology.

LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Y. Ohe, B. Chewaskulyong, E. Cho, 2017 .

Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (INFORM; C-TONG 0804).

M. Wang, X. Liu, Y. Cheng, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial

G. Hortobagyi, J. Baselga, P. Nuciforo, 2018 .

AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS).

M. Ahn, Y. Wu, C. Zhou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

P. Jänne, E. Felip, D. Planchard, 2022, Annals of Oncology.

Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors

Y. Lu, L. Wang, Y. Cheng, 2023, ESMO open.

M. Wang, X. Liu, Y. Cheng, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

B. Han, K. Nan, F. Jin, 2018, Journal of Thoracic Oncology.

P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis

Yuehua Wu, X. Liu, Jian-hua Chang, 2017 .

VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

S. Lu, Y. Cheng, B. Li, 2021, Annals of Oncology.

Concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma: treatment results from a prospective observational study.

Jun Liu, Y. Cheng, W. Fang, 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

EFFECTS OF CIJI HUA’AI BAOSHENG FORMULA ON APOPTOSIS CORRELATION FACTORS OF TUMOR CHEMOTHERAPY MODEL MOUSE WITH H22 HEPATOMA CARCINOMA CELLS

Y. Cheng, Yitao Wang, Shengyan Xi, 2015, African Journal of Traditional, Complementary and Alternative Medicines.

O-0023CONCUR: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF REGORAFENIB MONOTHERAPY IN ASIAN PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (MCRC)

Jianming Xu, R. Xu, H. Pan, 2014 .

A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT).

Y. Wu, C. Zhou, S. Lu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA02.03 The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI

J. Fang, T. Hsia, J. Chen, 2019, Journal of Thoracic Oncology.

EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment

T. Mok, Y. Ichinose, Takao Takahashi, 2016 .

A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).

Yangyang Shi, N. Xu, C. Zhou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dynamic Monitoring of Response Heterogeneity between Primary and Metastases Reveals Resistance Molecular Mechanisms in Advanced Non-Small Cell Lung Cancer with Acquired Resistance to EGFR-TKIs.

Xinzhe Dong, L. Xing, H. Wan, 2019, International Journal of Radiation Oncology*Biology*Physics.

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.

Y. Ohe, S. Ramalingam, B. Cho, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012 .

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA-05First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial

L. Wang, Jin Li, Y. Cheng, 2016 .

1354POsimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS)

M. Ahn, Y. Wu, C. Zhou, 2017 .

P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC

X. Jiang, J. Fang, F. Wu, 2021 .

MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

Y. Wang, P. Keegan, D. Zhong, 2021, Journal of Thoracic Oncology.

OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

X. Jiang, J. Fang, C. Zhu, 2019, Journal of Thoracic Oncology.

LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study

Y. Cheng, S. Cang, C. Ding, 2022, Annals of Oncology.

85P Adjuvant osimertinib in patients (pts) with stage IB–IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis

L. Shan, A. Atasoy, Y. Wu, 2022, Annals of Oncology.

MA02.01 Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

C. Zhou, Y. Cheng, J. Shao, 2021, Journal of Thoracic Oncology.

Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395].

T. Mitsudomi, J. Ying, Y. Shu, 2022, ESMO open.

265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial

Y. Cheng, J. Qin, J. Zhang, 2020, Annals of Oncology.

Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC).

Y. Wu, Y. Cheng, H. Pan, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study.

P-C. Yang, Y. Cheng, J. Kim, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC

P. Dennis, Y. Wu, Y. Cheng, 2019, Annals of Oncology.